Cargando…

Overall Structural Alteration of Gut Microbiota and Relationships with Risk Factors in Patients with Metabolic Syndrome Treated with Inulin Alone and with Other Agents: An Open-Label Pilot Study

OBJECTIVE: The relative contribution of some products with prebiotic effects, such as inulin, together with medications specific to the human gut microbiome has not been comprehensively studied. The present study determined the potential for manipulating populations in the gut microbiome using inuli...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Ruiping, Hong, Jiahui, Zhao, Jingjie, Zhou, Dengyuan, Liu, Yangchen, Jiao, Zhenshan, Song, Jian, Zhang, Yu, Meng, Lingzhang, Yu, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9136633/
https://www.ncbi.nlm.nih.gov/pubmed/35633654
http://dx.doi.org/10.1155/2022/2078520
_version_ 1784714226168758272
author Tian, Ruiping
Hong, Jiahui
Zhao, Jingjie
Zhou, Dengyuan
Liu, Yangchen
Jiao, Zhenshan
Song, Jian
Zhang, Yu
Meng, Lingzhang
Yu, Ming
author_facet Tian, Ruiping
Hong, Jiahui
Zhao, Jingjie
Zhou, Dengyuan
Liu, Yangchen
Jiao, Zhenshan
Song, Jian
Zhang, Yu
Meng, Lingzhang
Yu, Ming
author_sort Tian, Ruiping
collection PubMed
description OBJECTIVE: The relative contribution of some products with prebiotic effects, such as inulin, together with medications specific to the human gut microbiome has not been comprehensively studied. The present study determined the potential for manipulating populations in the gut microbiome using inulin alone and combined with other agents in individuals with metabolic syndrome (MetS). The study also assessed whether there is relationship variability in multiple clinical parameters in response to intervention with the changes in the gut milieu. Participants/Methods. This single-centre, single-blinded, randomised community-based pilot trial randomly assigned 60 patients (mean age, 46.3 y and male, 43%) with MetS to receive either inulin, inulin+traditional Chinese medicine (TCM), or inulin+metformin for 6 months. Lipid profiles, blood glucose, and uric acid (UA) levels were analysed in venous blood samples collected after overnight fast of 8 h at baseline and at the end of the follow-up period. Microbiota from stool samples were taxonomically analysed using 16S RNA amplicon sequencing, and an integrative analysis was conducted on microbiome and responsiveness data at 6 months. RESULTS: The results of 16S rRNA sequencing showed that inulin resulted in a higher proportion of Bacteroides at the endpoint compared with inulin+TCM and inulin+metformin (p = 0.024). More Romboutsia (p = 0.043), Streptococcus (p < 0.001), and Holdemanella (p = 0.011) were found in inulin+TCM and inulin+metformin samples. We further identified gut microbiota relationships with lipids, UA, and glucose that impact the development of MetS. CONCLUSION: Among the groups, inulin alone or combined with metformin or TCM altered specific gut microbiota taxa but not the general diversity. Accordingly, we analysed metabolites associated with microbiota that might provide more information about intrinsic differences. Consequently, a reliable method could be developed for treating metabolic syndrome in the future.
format Online
Article
Text
id pubmed-9136633
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-91366332022-05-28 Overall Structural Alteration of Gut Microbiota and Relationships with Risk Factors in Patients with Metabolic Syndrome Treated with Inulin Alone and with Other Agents: An Open-Label Pilot Study Tian, Ruiping Hong, Jiahui Zhao, Jingjie Zhou, Dengyuan Liu, Yangchen Jiao, Zhenshan Song, Jian Zhang, Yu Meng, Lingzhang Yu, Ming Mediators Inflamm Research Article OBJECTIVE: The relative contribution of some products with prebiotic effects, such as inulin, together with medications specific to the human gut microbiome has not been comprehensively studied. The present study determined the potential for manipulating populations in the gut microbiome using inulin alone and combined with other agents in individuals with metabolic syndrome (MetS). The study also assessed whether there is relationship variability in multiple clinical parameters in response to intervention with the changes in the gut milieu. Participants/Methods. This single-centre, single-blinded, randomised community-based pilot trial randomly assigned 60 patients (mean age, 46.3 y and male, 43%) with MetS to receive either inulin, inulin+traditional Chinese medicine (TCM), or inulin+metformin for 6 months. Lipid profiles, blood glucose, and uric acid (UA) levels were analysed in venous blood samples collected after overnight fast of 8 h at baseline and at the end of the follow-up period. Microbiota from stool samples were taxonomically analysed using 16S RNA amplicon sequencing, and an integrative analysis was conducted on microbiome and responsiveness data at 6 months. RESULTS: The results of 16S rRNA sequencing showed that inulin resulted in a higher proportion of Bacteroides at the endpoint compared with inulin+TCM and inulin+metformin (p = 0.024). More Romboutsia (p = 0.043), Streptococcus (p < 0.001), and Holdemanella (p = 0.011) were found in inulin+TCM and inulin+metformin samples. We further identified gut microbiota relationships with lipids, UA, and glucose that impact the development of MetS. CONCLUSION: Among the groups, inulin alone or combined with metformin or TCM altered specific gut microbiota taxa but not the general diversity. Accordingly, we analysed metabolites associated with microbiota that might provide more information about intrinsic differences. Consequently, a reliable method could be developed for treating metabolic syndrome in the future. Hindawi 2022-05-19 /pmc/articles/PMC9136633/ /pubmed/35633654 http://dx.doi.org/10.1155/2022/2078520 Text en Copyright © 2022 Ruiping Tian et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Tian, Ruiping
Hong, Jiahui
Zhao, Jingjie
Zhou, Dengyuan
Liu, Yangchen
Jiao, Zhenshan
Song, Jian
Zhang, Yu
Meng, Lingzhang
Yu, Ming
Overall Structural Alteration of Gut Microbiota and Relationships with Risk Factors in Patients with Metabolic Syndrome Treated with Inulin Alone and with Other Agents: An Open-Label Pilot Study
title Overall Structural Alteration of Gut Microbiota and Relationships with Risk Factors in Patients with Metabolic Syndrome Treated with Inulin Alone and with Other Agents: An Open-Label Pilot Study
title_full Overall Structural Alteration of Gut Microbiota and Relationships with Risk Factors in Patients with Metabolic Syndrome Treated with Inulin Alone and with Other Agents: An Open-Label Pilot Study
title_fullStr Overall Structural Alteration of Gut Microbiota and Relationships with Risk Factors in Patients with Metabolic Syndrome Treated with Inulin Alone and with Other Agents: An Open-Label Pilot Study
title_full_unstemmed Overall Structural Alteration of Gut Microbiota and Relationships with Risk Factors in Patients with Metabolic Syndrome Treated with Inulin Alone and with Other Agents: An Open-Label Pilot Study
title_short Overall Structural Alteration of Gut Microbiota and Relationships with Risk Factors in Patients with Metabolic Syndrome Treated with Inulin Alone and with Other Agents: An Open-Label Pilot Study
title_sort overall structural alteration of gut microbiota and relationships with risk factors in patients with metabolic syndrome treated with inulin alone and with other agents: an open-label pilot study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9136633/
https://www.ncbi.nlm.nih.gov/pubmed/35633654
http://dx.doi.org/10.1155/2022/2078520
work_keys_str_mv AT tianruiping overallstructuralalterationofgutmicrobiotaandrelationshipswithriskfactorsinpatientswithmetabolicsyndrometreatedwithinulinaloneandwithotheragentsanopenlabelpilotstudy
AT hongjiahui overallstructuralalterationofgutmicrobiotaandrelationshipswithriskfactorsinpatientswithmetabolicsyndrometreatedwithinulinaloneandwithotheragentsanopenlabelpilotstudy
AT zhaojingjie overallstructuralalterationofgutmicrobiotaandrelationshipswithriskfactorsinpatientswithmetabolicsyndrometreatedwithinulinaloneandwithotheragentsanopenlabelpilotstudy
AT zhoudengyuan overallstructuralalterationofgutmicrobiotaandrelationshipswithriskfactorsinpatientswithmetabolicsyndrometreatedwithinulinaloneandwithotheragentsanopenlabelpilotstudy
AT liuyangchen overallstructuralalterationofgutmicrobiotaandrelationshipswithriskfactorsinpatientswithmetabolicsyndrometreatedwithinulinaloneandwithotheragentsanopenlabelpilotstudy
AT jiaozhenshan overallstructuralalterationofgutmicrobiotaandrelationshipswithriskfactorsinpatientswithmetabolicsyndrometreatedwithinulinaloneandwithotheragentsanopenlabelpilotstudy
AT songjian overallstructuralalterationofgutmicrobiotaandrelationshipswithriskfactorsinpatientswithmetabolicsyndrometreatedwithinulinaloneandwithotheragentsanopenlabelpilotstudy
AT zhangyu overallstructuralalterationofgutmicrobiotaandrelationshipswithriskfactorsinpatientswithmetabolicsyndrometreatedwithinulinaloneandwithotheragentsanopenlabelpilotstudy
AT menglingzhang overallstructuralalterationofgutmicrobiotaandrelationshipswithriskfactorsinpatientswithmetabolicsyndrometreatedwithinulinaloneandwithotheragentsanopenlabelpilotstudy
AT yuming overallstructuralalterationofgutmicrobiotaandrelationshipswithriskfactorsinpatientswithmetabolicsyndrometreatedwithinulinaloneandwithotheragentsanopenlabelpilotstudy